Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
02:00am, Wednesday, 03'rd Jun 2026
Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
10:48am, Tuesday, 02'nd Jun 2026
An upcoming trial result could change how investors think about the weight-loss drug market.
Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
08:59am, Monday, 01'st Jun 2026
Novo Nordisk's (NYSE:NVO) oral GLP-1 weight-loss drug Wegovy pill continues to outsell Eli Lilly's recently launched competing tablet, but weekly prescription growth is slowing as the market absorbs a
Novo Nordisk A/S - share repurchase programme
07:17am, Monday, 01'st Jun 2026
Bagsværd, Denmark, 1 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now
12:15pm, Thursday, 28'th May 2026
Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.
Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables
09:07am, Thursday, 28'th May 2026
Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma g
Wall Street Underestimates Novo Nordisk's GLP-1 Comeback
08:59am, Thursday, 28'th May 2026
Despite Wall Street skepticism, Novo Nordisk A/S is starting to catch up with Eli Lilly, the market leader in the GLP-1s market. This skepticism mainly reflects declining demand for Ozempic, as well a
Completion of Tranche 2 of Placement
08:27am, Thursday, 28'th May 2026
Not for release to US wire service or distribution in the United States PERTH, Australia, May 28, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (ASX: NVO) (TSX: NVO)
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?
04:00pm, Wednesday, 27'th May 2026
There is no reason to panic just yet.
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
02:02pm, Wednesday, 27'th May 2026
Eli Lilly's fundamentals matter more than Trump's stock purchases.
Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
11:37am, Wednesday, 27'th May 2026
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
Ozempic, Other Weight Drug Users Cut Back On Eating Out. What That Means For Restaurants.
01:36pm, Tuesday, 26'th May 2026
More than 70% of GLP-1 users in the UBS Evidence Lab survey are eating less fast food.
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
11:17am, Tuesday, 26'th May 2026
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Novo Nordisk A/S - share repurchase programme
10:16am, Tuesday, 26'th May 2026
Bagsværd, Denmark, 26 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
09:51am, Tuesday, 26'th May 2026
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
